A PAF receptor antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

LAU-0901

Item No. 38414

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylic acid, 3-[2-(3,4-dichlorophenoxy)ethyl] 5-[2-(4-morpholinyl)-1-(4-morpholinylmethyl)ethyl] ester
CAS Number
727358-25-0
Molecular Formula
C29H39Cl2N3O7
Formula Weight
612.5
Purity
≥95%
Formulation
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Soluble
SMILES
O=C(C1=C(C)NC(C)=C(C1C)C(OC(CN2CCOCC2)CN3CCOCC3)=O)OCCOC4=CC=C(C(Cl)=C4)Cl
InChi Code
InChI=1S/C29H39Cl2N3O7/c1-19-26(28(35)40-15-14-39-22-4-5-24(30)25(31)16-22)20(2)32-21(3)27(19)29(36)41-23(17-33-6-10-37-11-7-33)18-34-8-12-38-13-9-34/h4-5,16,19,23,32H,6-15,17-18H2,1-3H3
InChi Key
WZWJKBCMEZITJW-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $44

    Add

    5 mg

    $164

    Add

    10 mg

    $242

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    LAU-0901 is a platelet-activating factor (PAF) receptor antagonist.1,2 In vivo, LAU-0901 (30, 60, and 90 mg/kg) reduces infarct volume and improves neurological function in a rat model of cerebral ischemia induced by middle cerebral artery occlusion (MCAO).1 It also reduces microglial infiltration and increases astrocytic and neuronal survival in the same model.2 LAU-0901 (30 mg/kg) alone, or in combination with atorvastatin (Item No. 10453), reduces tumor growth in a U87MG glioblastoma mouse orthotopic tumor model.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Belayev, L., Khoutorova, L., Atkins, K., et al. LAU-0901, a novel platelet-activating factor antagonist, is highly neuroprotective in cerebral ischemia. Exp. Neurol. 214(2), 253-258 (2008).

    2. Belayev, L., Eady, T.N., Khoutorova, L., et al. Superior neuroprotective efficacy of LAU-0901, a novel platelet-activating factor antagonist, in experimental stroke. Transl. Stroke Res. 3(1), 154-163 (2012).

    3. Cruz Flores, V.A., Menghani, H., Mukherjee, P.K., et al. Combined therapy with avastin, a PAF receptor antagonist and a lipid mediator inhibited glioblastoma tumor growth. Front. Pharmacol. 12, 746470 (2021).